Stay updated on Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4. This indicates a patch-level update to the page's documentation or content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check38 days agoChange DetectedThe page’s technical revision/version tag was updated from v3.5.0 to v3.5.3 without changing the study details.SummaryDifference0.0%

- Check59 days agoChange DetectedRELIVE trial publication citation added (Lancet Gastroenterol Hepatol, 2019) and the related erratum entry removed.SummaryDifference0.0%

- Check73 days agoChange DetectedAdds the term 'Hepatocellular carcinoma' to the page content and includes the Genetic and Rare Diseases Information Center as a resource. Updates the site revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check88 days agoChange DetectedAdded the RELIVE publication citation (Lancet Gastroenterol Hepatol 2019) with revision v3.4.3 and removed the earlier v3.4.2 citation.SummaryDifference0.1%

- Check109 days agoChange DetectedThe site shows a revision label change from v3.4.1 to v3.4.2; no substantive changes to the study details or related content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.